How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Buy
66
HALO Quote, Financials, Valuation and Earnings
Last price:
$58.19
Seasonality move
:
9.6%
Day range:
$57.40 - $58.44
52-week range:
$37.97 - $66.00
Dividend yield:
0%
P/E ratio:
16.97x
P/S ratio:
7.42x
P/B ratio:
19.70x
Volume:
1.4M
Avg. volume:
1.6M
1-year change:
50.37%
Market cap:
$7.2B
Revenue:
$1B
EPS (TTM):
$3.43
Analysts' Opinion
-
Consensus RatingHalozyme Therapeutics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $68.13, Halozyme Therapeutics has an estimated upside of 17.03% from its current price of $58.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $58.00 representing 100% downside risk from its current price of $58.21.
Fair Value
-
According to the consensus of 6 analysts, Halozyme Therapeutics has 17.03% upside to fair value with a price target of $68.13 per share.
HALO vs. S&P 500
-
Over the past 5 trading days, Halozyme Therapeutics has underperformed the S&P 500 by -5.27% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Halozyme Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Halozyme Therapeutics has grown year-over-year revenues for 12 quarters straight. In the most recent quarter Halozyme Therapeutics reported revenues of $298M.
Earnings Growth
-
Halozyme Therapeutics has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Halozyme Therapeutics reported earnings per share of $1.06.
Enterprise value:
8.1B
EV / Invested capital:
--
Price / LTM sales:
7.42x
EV / EBIT:
14.04x
EV / Revenue:
7.96x
PEG ratio (5yr expected):
0.27x
EV / Free cash flow:
17.25x
Price / Operating cash flow:
16.07x
Enterprise value / EBITDA:
12.30x
Gross Profit (TTM):
$855.9M
Return On Assets:
22.83%
Net Income Margin (TTM):
43.74%
Return On Equity:
162.37%
Return On Invested Capital:
25.01%
Operating Margin:
58.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $660.1M | $829.3M | $1B | $230M | $298M | |
| Gross Profit | $520.8M | $636.9M | $855.9M | $177.7M | $256M | |
| Operating Income | $267.5M | $337.6M | $551.5M | $101M | $175.5M | |
| EBITDA | $315.5M | $451.9M | $656.5M | $127.1M | $203.2M | |
| Diluted EPS | $1.45 | $2.11 | $3.43 | $0.65 | $1.06 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $554.8M | $926.3M | $739M | $746.4M | $1.1B | |
| Total Assets | $579.9M | $1.1B | $1.8B | $1.7B | $2.1B | |
| Current Liabilities | $421.4M | $117.1M | $130.8M | $112.5M | $139.1M | |
| Total Liabilities | $428.9M | $907.5M | $1.7B | $1.6B | $1.7B | |
| Total Equity | $151M | $197M | $169.8M | $83.8M | $363.8M | |
| Total Debt | $397.2M | $876.7M | $1.5B | $1.5B | $1.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $240.1M | $388.6M | $479.1M | $102.4M | $178.5M | |
| Cash From Investing | -$487M | -$96.9M | -$262.7M | -$8.3M | $29.5M | |
| Cash From Financing | $362.4M | -$408M | -$218.9M | -$249.9M | -$246.4M | |
| Free Cash Flow | $235.3M | $373.3M | $468.4M | $99.8M | $175.4M | |
HALO
Sector
Market Cap
$7.2B
$34.2M
Price % of 52-Week High
88.2%
42.23%
Dividend Yield
0%
0%
Shareholder Yield
4.22%
-0.82%
1-Year Price Total Return
50.38%
-41.76%
Beta (5-Year)
1.323
0.737
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$59.21
200-day SMA
Buy
Level
$55.81
Bollinger Bands (100)
Buy
Level
49.94 - 61.22
Chaikin Money Flow
Buy
Level
96.4M
20-day SMA
Sell
Level
$60.93
Relative Strength Index (RSI14)
Sell
Level
43.47
ADX Line
Sell
Level
31.43
Williams %R
Neutral
Level
-66.3526
50-day SMA
Sell
Level
$60.25
MACD (12, 26)
Sell
Level
-0.68
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
261.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.2847)
Sell
CA Score
(Annual)
Level (-0.6438)
Buy
Beneish M-Score
(Annual)
Level (-2.3886)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.2417)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Stock Forecast FAQ
In the current month, HALO has received 3 Buy ratings 3 Hold ratings, and 0 Sell ratings. The HALO average analyst price target in the past 3 months is $68.13.
-
Where Will Halozyme Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Halozyme Therapeutics share price will rise to $68.13 per share over the next 12 months.
-
What Do Analysts Say About Halozyme Therapeutics?
Analysts are divided on their view about Halozyme Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Halozyme Therapeutics is a Sell and believe this share price will drop from its current level to $58.00.
-
What Is Halozyme Therapeutics's Price Target?
The price target for Halozyme Therapeutics over the next 1-year time period is forecast to be $68.13 according to 6 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is HALO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Halozyme Therapeutics is a Leans Bullish. 3 of 6 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of HALO?
You can purchase shares of Halozyme Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Halozyme Therapeutics shares.
-
What Is The Halozyme Therapeutics Share Price Today?
Halozyme Therapeutics was last trading at $58.19 per share. This represents the most recent stock quote for Halozyme Therapeutics. Yesterday, Halozyme Therapeutics closed at $58.21 per share.
-
How To Buy Halozyme Therapeutics Stock Online?
In order to purchase Halozyme Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TSMC the Best Semiconductor Stock to Buy Now?
The new administration has launched a slew of tariffs, paused…
Rocket Lab Vs Intuitive Machines Stock
The commercialization of outer space is now in full swing,…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 34x
Alerts
Buy
72
EFX alert for Apr 23
Equifax [EFX] is up 13.86% over the past day.
Buy
51
CALX alert for Apr 23
Calix [CALX] is up 13.26% over the past day.
Sell
38
NOC alert for Apr 23
Northrop Grumman [NOC] is down 12.3% over the past day.
